Apo E genotypes in multiple sclerosis, Parkinson's disease, schwannomas and late-onset Alzheimer's disease

1994 ◽  
Vol 8 (6) ◽  
pp. 519-525 ◽  
Author(s):  
David C. Rubinsztein ◽  
Charlotte S. Hanlon ◽  
Richard M. Irving ◽  
Sandy Goodburn ◽  
D.Gareth R. Evans ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Late Onset ◽  
Apo E

scholarly journals Brain Aging and Gut–Brain Axis

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 424 ◽  
Author(s):  
M. Mohajeri
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Brain Development ◽  
Neurodegenerative Disorders ◽  
Gut Microbiome ◽  
Brain Aging ◽  
And Function

In the last decade, the microbiome in general and the gut microbiome in particular have been associated not only to brain development and function, but also to the pathophysiology of brain aging and to neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), depression, or multiple sclerosis (MS) [...]

Nutrition in neurological conditions

2020 ◽  
pp. 781-794
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Motor Neurone ◽  
Motor Neurone Disease ◽  
Neurological Conditions

Multiple sclerosis, Motor neurone disease, Parkinson’s disease, Alzheimer’s disease, Ketogenic therapy for epilepsy

Parkinson's disease-associated parkin colocalizes with Alzheimer's disease and multiple sclerosis brain lesions

2009 ◽  
Vol 36 (3) ◽  
pp. 445-452 ◽  
Author(s):  
Maarten E. Witte ◽  
John G.J.M. Bol ◽  
Wouter H. Gerritsen ◽  
Paul van der Valk ◽  
Benjamin Drukarch ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Brain Lesions

scholarly journals The Contribution of Small Vessel Disease to Neurodegeneration: Focus on Alzheimer’s Disease, Parkinson’s Disease and Multiple Sclerosis

2021 ◽  
Vol 22 (9) ◽  
pp. 4958
Author(s):  
Federico Paolini Paoletti ◽  
Simone Simoni ◽  
Lucilla Parnetti ◽  
Lorenzo Gaetani
Keyword(s):  
Multiple Sclerosis ◽  
Alzheimer’S Disease ◽  
Parkinson’S Disease ◽  
Alzheimer's Disease ◽  
Parkinson's Disease ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease ◽  
Immune System Activation ◽  
The Impact

Brain small vessel disease (SVD) refers to a variety of structural and functional changes affecting small arteries and micro vessels, and manifesting as white matter changes, microbleeds and lacunar infarcts. Growing evidence indicates that SVD might play a significant role in the neurobiology of central nervous system (CNS) neurodegenerative disorders, namely Alzheimer’s disease (AD) and Parkinson’s disease (PD), and neuroinflammatory diseases, such as multiple sclerosis (MS). These disorders share different pathophysiological pathways and molecular mechanisms (i.e., protein misfolding, derangement of cellular clearance systems, mitochondrial impairment and immune system activation) having neurodegeneration as biological outcome. In these diseases, the actual contribution of SVD to the clinical picture, and its impact on response to pharmacological treatments, is not known yet. Due to the high frequency of SVD in adult-aged patients, it is important to address this issue. In this review, we report preclinical and clinical data on the impact of SVD in AD, PD and MS, with the main aim of clarifying the predictability of SVD on clinical manifestations and treatment response.

Sign in / Sign up

Export Citation Format

Share Document